...
首页> 外文期刊>Molecular pharmaceutics >Lipid digestion as a trigger for supersaturation: Evaluation of the impact of supersaturation stabilization on the in vitro and in vivo performance of self-emulsifying drug delivery systems
【24h】

Lipid digestion as a trigger for supersaturation: Evaluation of the impact of supersaturation stabilization on the in vitro and in vivo performance of self-emulsifying drug delivery systems

机译:脂质消化引发过饱和:评估过饱和稳定性对自乳化药物递送系统体外和体内性能的影响

获取原文
获取原文并翻译 | 示例
           

摘要

The generation of supersaturation in the gastrointestinal (GI) tract is an increasingly popular means of promoting oral absorption for poorly water-soluble drugs. The current study examined the impact of changes to the quantities of medium-chain (MC) lipid (Captex 300:Capmul MCM), surfactant (Cremophor EL) and cosolvent (EtOH), and the addition of polymeric precipitation inhibitors (PPI), on supersaturation during the dispersion and digestion of MC self-emulsifying drug delivery systems (SEDDS) containing danazol. The data suggest that digestion acts as a "trigger" for enhanced supersaturation and that solubilization/precipitation behavior is correlated with the degree of supersaturation on dispersion (S M DISP) or digestion (S M DIGEST). The ability of the formulation to maintain solubilization in vitro decreased as the S M of the formulation increased. PPI significantly increased supersaturation stabilization and precipitation was inhibited where S M DISP 3.5 and S M DIGEST 4. In the presence of polymer, some degree of supersaturation was maintained up to S M DIGEST ~ 8. Differentiation in the ability of SEDDS to maintain drug solubilization stems from the ability to stabilize supersaturation and for MC SEDDS, utilization of lower drug loads, higher surfactant levels (balanced against increases in S M DISP), lower cosolvent and the addition of PPI enhanced formulation performance. In vivo studies confirmed the ability of PPI to promote drug exposure at moderate drug loads (40% of saturated solubility in the formulation). At higher drug loads (80% saturation) and in lipid-free SEDDS, this effect was lost, suggesting that the ability of PPIs to stabilize supersaturation in vitro may, under some circumstances, overestimate utility in vivo.
机译:胃肠道(GI)中过饱和的产生是促进水溶性差的药物口服吸收的一种日益流行的手段。当前的研究检查了中链(MC)脂质(Captex 300:Capmul MCM),表面活性剂(Cremophor EL)和助溶剂(EtOH)的量变化以及聚合物沉淀抑制剂(PPI)的添加对聚合物的影响。含达那唑的MC自乳化药物传递系统(SEDDS)的分散和消化过程中过饱和。数据表明,消化作用是增强过饱和度的“触发”,并且增溶/沉淀行为与分散度(S M DISP)或消化作用(S M DIGEST)的过饱和度相关。随着制剂的S M增加,制剂在体外维持增溶的能力降低。 PDIS显着提高了过饱和稳定性,在SM DISP <3.5和SM DIGEST <4的情况下,沉淀被抑制。在聚合物存在下,SM DIGEST〜8保持一定程度的过饱和。从稳定过饱和和MC SEDDS的能力,使用较低的药物负荷,较高的表面活性剂水平(与SM DISP的增加平衡),较低的助溶剂和PPI的添加增强了制剂性能。体内研究证实了PPI具有在中等载药量(制剂中40%的饱和溶解度)下促进药物暴露的能力。在较高的药物负荷(饱和度为80%)和无脂质SEDDS中,这种作用消失了,这表明在某些情况下PPI稳定体外过饱和的能力可能会高估体内的效用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号